<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962740</url>
  </required_header>
  <id_info>
    <org_study_id>13-043</org_study_id>
    <nct_id>NCT01962740</nct_id>
  </id_info>
  <brief_title>Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)</brief_title>
  <acronym>STRUT-OCT</acronym>
  <official_title>Serial Evaluation of Drug-Eluting Stents Using OCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Texas Veterans Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Texas Veterans Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is proposed as a 48-patient randomized-controlled pilot study that will use Optical
      Coherence Tomography (OCT) imaging to compare stent strut coverage and malapposition of three
      second-generation Drug Eluting Stents (DES) [Xience EES (Abbott Vascular, Santa Clara, CA),
      Resolute Integrity ZES (Medtronic, Minneapolis, MN) and Promus Element EES (Boston
      Scientific, Natick, MA)] at 6 weeks post implantation.

      Study Hypothesis is that the rates of stent strut coverage and malapposition of the Xience
      EES, Promus EES and will be similar to each other and improved (higher rates of stent strut
      coverage and lower rates of malapposition) compared to the Resolute ZES at 6 weeks
      post-implantation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of eligible patients
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stent Strut Coverage</measure>
    <time_frame>6 weeks post-implantation</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stent Strut Malapposition</measure>
    <time_frame>6 weeks post-implantation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Drug Eluting Stents (DES)</condition>
  <condition>Percutaneous Coronary Intervention (PCI)</condition>
  <condition>Uncovered and Malapposed Stent Struts</condition>
  <condition>Optical Coherence Tomography (OCT)</condition>
  <arm_group>
    <arm_group_label>Xience EES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm of patients will receive Xience Everolimus Eluting Stents(EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resolute Integrity ZES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm of patients will receive Resolute Integrity Zotaralimus Eluting Stents (ZES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Promus Element EES</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm of patients will receive Promus Element Everolimus Eluting Stents (EES) as part of their clinically indicated PCI procedure and they will undergo Optical Coherence Tomography Imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-eluting stent implantation</intervention_name>
    <arm_group_label>Xience EES</arm_group_label>
    <arm_group_label>Resolute Integrity ZES</arm_group_label>
    <arm_group_label>Promus Element EES</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age greater than or equal to 18 years

          2. Clinical need for percutaneous coronary intervention using either a Xience, Promus
             Element, or Resolute Integrity drug-eluting stent using optical coherence tomography
             optimization

          3. Native coronary artery de novo lesion with ≥70% angiographic percent diameter stenosis
             by visual estimation

          4. Target vessel reference diameter between 2.5 and 4.0 mm by visual estimate

          5. Target lesion ≤28 mm in length by visual estimate

          6. Agree to participate and provide informed consent

        Exclusion Criteria:

        1.Presentation with acute ST-elevation myocardial infarction (defined as
        electrocardiographic (ECG) ST-elevation ≥ 2 mm in 2 or more contiguous ECG leads along with
        symptoms compatible with ischemia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuaib Abdullah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Texas Veterans Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA North Texas Health Care System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>North Texas Veterans Healthcare System</investigator_affiliation>
    <investigator_full_name>Shuaib Abdullah, MD</investigator_full_name>
    <investigator_title>Cardiologist; Assistant Professor, Division of Cardiology, Internal Medicine, UT Southwestern Medical School</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

